Literature DB >> 911195

Effects of 8-methoxypsoralen (8-MOP) and UVA on human lymphocytes.

G Lischka, E Bohnert, G Bächtold, E G Jung.   

Abstract

Peripheral lymphocytes of 37 psoriatic patients are tested before and under PUVA treatment using as parameter the non specific stimulation effect of HgCl2 (10 microgram/ml) in culture, measuring the 3H-thymidine incorporation after the last 16 h of a 5-days culture. Oral 8-MOP in therapeutic doses is decreasing the lymphocyte stimulation as well as 8-MOP together with UVA irradiation during the first week of treatment. After 1 week, the stimulation is, on the contrary, significantly enhanced after irradiation. Lymphocytes isolated by centrifugation over Lymphoprep are submitted to PUVA conditions in petri dishes (Hank's solution 8-MOP 1 microgram/ml, irradiation with 350 nm, 93-372 mJ/cm2). The total cell number, the E-rosette formation (as marker for T-lymphocytes) and the EAC-rosette formation (as marker for B-lymphocytes) are determined. PUVA conditions have an energy dependent decreasing effect on the cell number, while the T- and B-cell proportions remain constant. UVA irradiation alone has such an effect only with high energies. 8-MOP without UVA has no significant influence on the cell number.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911195     DOI: 10.1007/bf00561456

Source DB:  PubMed          Journal:  Arch Dermatol Res            Impact factor:   3.017


  4 in total

1.  Immunological responses of patients with psoriasis and the effect of treatment with methotrexate.

Authors:  A Levantine; J Brostoff
Journal:  Br J Dermatol       Date:  1975-12       Impact factor: 9.302

2.  Immunological aspects of psoriasis. II. Dissociated impairment of thymus-dependent lymphocytes.

Authors:  J J Guilhou; J Meynadier; J Clot; E Charmasson; M Dardenne; J Brochier
Journal:  Br J Dermatol       Date:  1976-09       Impact factor: 9.302

3.  Selective T cell killing of human lymphocytes by ultraviolet radiation.

Authors:  S Horowitz; D Cripps; R Hong
Journal:  Cell Immunol       Date:  1974-10       Impact factor: 4.868

Review 4.  [Current aspects of the pathogenesis of skin manifestations in psoriasis vulgaris].

Authors:  O Braun-Falco
Journal:  Hautarzt       Date:  1976-08       Impact factor: 0.751

  4 in total
  9 in total

1.  Quantification of HTLA-positive lymphocytes during oral photochemotherapy of psoriasis.

Authors:  D Schmitt; J P Ortonne; A Alario; J Thivolet
Journal:  Arch Dermatol Res       Date:  1979-11       Impact factor: 3.017

2.  Immunologic implications of PUVA therapy in psoriasis vulgaris.

Authors:  R H Cormane; F Hamerlinck; A H Siddiqui
Journal:  Arch Dermatol Res       Date:  1979-07-30       Impact factor: 3.017

3.  [DNA-repair in lymphocytes after 8-MOP + UVA and UVC irradiation (author's transl)].

Authors:  E Bohnert; B Badilatti; P Sidler; E G Jung
Journal:  Arch Dermatol Res       Date:  1979-05-04       Impact factor: 3.017

4.  [DNA-repair of lymphocytes during PUVA-treatment (author's transl)].

Authors:  E Bohnert; W G Humbel
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

5.  Inhibitory effect of 8-methoxysporalen plus UVA (PUVA) on the systemic induction of contact sensitivity to dinitrochlorobenzene (DNCB) in guinea pigs.

Authors:  J C Meyer; H P Grundmann; H Weiss
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

6.  Stimulation of lymphocytes in patients with psoriasis under photochemotherapy. A study of lymphocyte transformation.

Authors:  S W Wassilew
Journal:  Arch Dermatol Res       Date:  1978-11-10       Impact factor: 3.017

7.  Dark effect of 8-methoxypsoralen (8-MOP) on lymphocytes.

Authors:  G Lischka; E Decker
Journal:  Arch Dermatol Res       Date:  1978-05-31       Impact factor: 3.017

8.  Lymphocyte proliferation during PUVA therapy.

Authors:  G Lischka
Journal:  Arch Dermatol Res       Date:  1979-06-25       Impact factor: 3.017

Review 9.  Photochemotherapy in psoriasis: a review.

Authors:  D V Briffa; A P Warin
Journal:  J R Soc Med       Date:  1979-06       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.